Expression  ||| S:0 E:11 ||| NN
and  ||| S:11 E:15 ||| CC
regulation  ||| S:15 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
COP1  ||| S:29 E:34 ||| CD
in  ||| S:34 E:37 ||| IN
chronic  ||| S:37 E:45 ||| JJ
lymphocytic  ||| S:45 E:57 ||| JJ
leukemia  ||| S:57 E:66 ||| NN
cells  ||| S:66 E:72 ||| NNS
for  ||| S:72 E:76 ||| IN
promotion  ||| S:76 E:86 ||| NN
of  ||| S:86 E:89 ||| IN
cell  ||| S:89 E:94 ||| NN
proliferation  ||| S:94 E:108 ||| NN
and  ||| S:108 E:112 ||| CC
tumorigenicity  ||| S:112 E:127 ||| FW
Chronic  ||| S:127 E:135 ||| FW
lymphocytic  ||| S:135 E:147 ||| FW
leukemia  ||| S:147 E:156 ||| FW
( ||| S:156 E:157 ||| -LRB-
CLL ||| S:157 E:160 ||| NNP
)  ||| S:160 E:162 ||| -RRB-
is  ||| S:162 E:165 ||| VBZ
the  ||| S:165 E:169 ||| DT
most  ||| S:169 E:174 ||| RBS
common  ||| S:174 E:181 ||| JJ
leukemia  ||| S:181 E:190 ||| NN
in  ||| S:190 E:193 ||| IN
Western  ||| S:193 E:201 ||| JJ
countries ||| S:201 E:210 ||| NNS
,  ||| S:210 E:212 ||| ,
and  ||| S:212 E:216 ||| CC
mainly  ||| S:216 E:223 ||| RB
originates  ||| S:223 E:234 ||| VBZ
from  ||| S:234 E:239 ||| IN
an  ||| S:239 E:242 ||| DT
accumulation  ||| S:242 E:255 ||| NN
of  ||| S:255 E:258 ||| IN
abnormal  ||| S:258 E:267 ||| JJ
B  ||| S:267 E:269 ||| NN
cells  ||| S:269 E:275 ||| NNS
caused  ||| S:275 E:282 ||| VBN
by  ||| S:282 E:285 ||| IN
the  ||| S:285 E:289 ||| DT
dysregulation  ||| S:289 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
cell  ||| S:306 E:311 ||| NN
proliferation  ||| S:311 E:325 ||| NN
and  ||| S:325 E:329 ||| CC
apoptosis ||| S:329 E:338 ||| NN
.  ||| S:338 E:340 ||| .
The  ||| S:340 E:344 ||| DT
aberration  ||| S:344 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
proliferation-related  ||| S:358 E:380 ||| JJ
gene  ||| S:380 E:385 ||| NN
in  ||| S:385 E:388 ||| IN
CLL  ||| S:388 E:392 ||| NNP
cells  ||| S:392 E:398 ||| NNS
induces  ||| S:398 E:406 ||| JJ
cell  ||| S:406 E:411 ||| NN
arrest  ||| S:411 E:418 ||| NN
at  ||| S:418 E:421 ||| IN
G0 ||| S:421 E:423 ||| CD
/ ||| S:423 E:424 ||| CD
G1  ||| S:424 E:427 ||| CD
phase ||| S:427 E:432 ||| NN
,  ||| S:432 E:434 ||| ,
or  ||| S:434 E:437 ||| CC
a  ||| S:437 E:439 ||| DT
small  ||| S:439 E:445 ||| JJ
section  ||| S:445 E:453 ||| NN
shows  ||| S:453 E:459 ||| VBZ
rapid  ||| S:459 E:465 ||| JJ
cell  ||| S:465 E:470 ||| NN
growth ||| S:470 E:476 ||| NN
,  ||| S:476 E:478 ||| ,
which  ||| S:478 E:484 ||| WDT
further  ||| S:484 E:492 ||| RB
complicates  ||| S:492 E:504 ||| VBZ
the  ||| S:504 E:508 ||| DT
pathogenesis  ||| S:508 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
CLL ||| S:524 E:527 ||| NNP
.  ||| S:527 E:529 ||| .
The  ||| S:529 E:533 ||| DT
constitutively  ||| S:533 E:548 ||| JJ
photomorphogenic  ||| S:548 E:565 ||| NN
1  ||| S:565 E:567 ||| CD
( ||| S:567 E:568 ||| -LRB-
COP1 ||| S:568 E:572 ||| NNP
) ||| S:572 E:573 ||| -RRB-
,  ||| S:573 E:575 ||| ,
as  ||| S:575 E:578 ||| IN
an  ||| S:578 E:581 ||| DT
E3  ||| S:581 E:584 ||| FW
ubiquitin  ||| S:584 E:594 ||| FW
ligase ||| S:594 E:600 ||| FW
,  ||| S:600 E:602 ||| ,
is  ||| S:602 E:605 ||| VBZ
involved  ||| S:605 E:614 ||| VBN
in  ||| S:614 E:617 ||| IN
many  ||| S:617 E:622 ||| JJ
biological  ||| S:622 E:633 ||| JJ
processes  ||| S:633 E:643 ||| NNS
in  ||| S:643 E:646 ||| IN
mammalian  ||| S:646 E:656 ||| JJ
cells ||| S:656 E:661 ||| NNS
,  ||| S:661 E:663 ||| ,
but  ||| S:663 E:667 ||| CC
its  ||| S:667 E:671 ||| PRP$
role  ||| S:671 E:676 ||| NN
in  ||| S:676 E:679 ||| IN
chronic  ||| S:679 E:687 ||| JJ
lymphocytic  ||| S:687 E:699 ||| JJ
leukemia  ||| S:699 E:708 ||| NN
( ||| S:708 E:709 ||| -LRB-
CLL ||| S:709 E:712 ||| NNP
)  ||| S:712 E:714 ||| -RRB-
progression  ||| S:714 E:726 ||| NN
remains  ||| S:726 E:734 ||| VBZ
unclear ||| S:734 E:741 ||| JJ
.  ||| S:741 E:743 ||| .
In  ||| S:743 E:746 ||| IN
the  ||| S:746 E:750 ||| DT
present  ||| S:750 E:758 ||| JJ
study ||| S:758 E:763 ||| NN
,  ||| S:763 E:765 ||| ,
we  ||| S:765 E:768 ||| PRP
analyzed  ||| S:768 E:777 ||| VBD
the  ||| S:777 E:781 ||| DT
expression  ||| S:781 E:792 ||| NN
of  ||| S:792 E:795 ||| IN
COP1  ||| S:795 E:800 ||| CD
in  ||| S:800 E:803 ||| IN
peripheral  ||| S:803 E:814 ||| JJ
blood  ||| S:814 E:820 ||| NN
mononuclear  ||| S:820 E:832 ||| NN
cells  ||| S:832 E:838 ||| NNS
( ||| S:838 E:839 ||| -LRB-
PBMCs ||| S:839 E:844 ||| NNP
)  ||| S:844 E:846 ||| -RRB-
from  ||| S:846 E:851 ||| IN
23  ||| S:851 E:854 ||| CD
CLL  ||| S:854 E:858 ||| NN
patients  ||| S:858 E:867 ||| NNS
and  ||| S:867 E:871 ||| CC
3  ||| S:871 E:873 ||| CD
healthy  ||| S:873 E:881 ||| JJ
donors ||| S:881 E:887 ||| NNS
.  ||| S:887 E:889 ||| .
The  ||| S:889 E:893 ||| DT
observed  ||| S:893 E:902 ||| JJ
upregulated  ||| S:902 E:914 ||| JJ
expression  ||| S:914 E:925 ||| NN
of  ||| S:925 E:928 ||| IN
COP1  ||| S:928 E:933 ||| CD
in  ||| S:933 E:936 ||| IN
CLL  ||| S:936 E:940 ||| NNP
patients  ||| S:940 E:949 ||| NNS
was  ||| S:949 E:953 ||| VBD
positively  ||| S:953 E:964 ||| RB
correlated  ||| S:964 E:975 ||| VBN
with  ||| S:975 E:980 ||| IN
CLL  ||| S:980 E:984 ||| NNP
clinical  ||| S:984 E:993 ||| JJ
stage  ||| S:993 E:999 ||| NN
and  ||| S:999 E:1003 ||| CC
ZAP-70  ||| S:1003 E:1010 ||| CD
expression ||| S:1010 E:1020 ||| NN
,  ||| S:1020 E:1022 ||| ,
but  ||| S:1022 E:1026 ||| CC
not  ||| S:1026 E:1030 ||| RB
del ||| S:1030 E:1033 ||| FW
( ||| S:1033 E:1034 ||| -LRB-
13q14 ||| S:1034 E:1039 ||| NNP
)  ||| S:1039 E:1041 ||| -RRB-
and  ||| S:1041 E:1045 ||| CC
del ||| S:1045 E:1048 ||| FW
( ||| S:1048 E:1049 ||| -LRB-
17q- ||| S:1049 E:1053 ||| NNP
) ||| S:1053 E:1054 ||| -RRB-
.  ||| S:1054 E:1056 ||| .
Overexpression  ||| S:1056 E:1071 ||| NNP
of  ||| S:1071 E:1074 ||| IN
COP1  ||| S:1074 E:1079 ||| NNP
significantly  ||| S:1079 E:1093 ||| RB
promoted  ||| S:1093 E:1102 ||| VBN
cell  ||| S:1102 E:1107 ||| NN
colony  ||| S:1107 E:1114 ||| NN
formation  ||| S:1114 E:1124 ||| NN
and  ||| S:1124 E:1128 ||| CC
proliferation ||| S:1128 E:1141 ||| NN
,  ||| S:1141 E:1143 ||| ,
especially  ||| S:1143 E:1154 ||| RB
contributing  ||| S:1154 E:1167 ||| VBG
to  ||| S:1167 E:1170 ||| TO
the  ||| S:1170 E:1174 ||| DT
accumulation  ||| S:1174 E:1187 ||| NN
of  ||| S:1187 E:1190 ||| IN
cells  ||| S:1190 E:1196 ||| NNS
in  ||| S:1196 E:1199 ||| IN
S-phase  ||| S:1199 E:1207 ||| JJ
by  ||| S:1207 E:1210 ||| IN
inhibition  ||| S:1210 E:1221 ||| NN
of  ||| S:1221 E:1224 ||| IN
FoxO1  ||| S:1224 E:1230 ||| NNP
and  ||| S:1230 E:1234 ||| CC
p21 ||| S:1234 E:1237 ||| NNP
.  ||| S:1237 E:1239 ||| .
Moreover ||| S:1239 E:1247 ||| RB
,  ||| S:1247 E:1249 ||| ,
overexpression  ||| S:1249 E:1264 ||| VBG
of  ||| S:1264 E:1267 ||| IN
COP1  ||| S:1267 E:1272 ||| NNP
accelerated  ||| S:1272 E:1284 ||| VBD
tumorigenicity  ||| S:1284 E:1299 ||| VBN
of  ||| S:1299 E:1302 ||| IN
HG3  ||| S:1302 E:1306 ||| CD
cells  ||| S:1306 E:1312 ||| NNS
and  ||| S:1312 E:1316 ||| CC
promoted  ||| S:1316 E:1325 ||| VBN
xenograft  ||| S:1325 E:1335 ||| JJ
growth ||| S:1335 E:1341 ||| NN
.  ||| S:1341 E:1343 ||| .
Therefore ||| S:1343 E:1352 ||| RB
,  ||| S:1352 E:1354 ||| ,
the  ||| S:1354 E:1358 ||| DT
present  ||| S:1358 E:1366 ||| JJ
study  ||| S:1366 E:1372 ||| NN
revealed  ||| S:1372 E:1381 ||| VBD
that  ||| S:1381 E:1386 ||| IN
COP1  ||| S:1386 E:1391 ||| NNP
plays  ||| S:1391 E:1397 ||| VBZ
an  ||| S:1397 E:1400 ||| DT
important  ||| S:1400 E:1410 ||| JJ
role  ||| S:1410 E:1415 ||| NN
in  ||| S:1415 E:1418 ||| IN
CLL  ||| S:1418 E:1422 ||| NNP
cell  ||| S:1422 E:1427 ||| NN
proliferation  ||| S:1427 E:1441 ||| NN
and  ||| S:1441 E:1445 ||| CC
tumorigenicity ||| S:1445 E:1459 ||| NN
,  ||| S:1459 E:1461 ||| ,
and  ||| S:1461 E:1465 ||| CC
may  ||| S:1465 E:1469 ||| MD
be  ||| S:1469 E:1472 ||| VB
a  ||| S:1472 E:1474 ||| DT
useful  ||| S:1474 E:1481 ||| JJ
indicator  ||| S:1481 E:1491 ||| NN
of  ||| S:1491 E:1494 ||| IN
the  ||| S:1494 E:1498 ||| DT
chronic  ||| S:1498 E:1506 ||| JJ
lymphocytic  ||| S:1506 E:1518 ||| JJ
leukemia  ||| S:1518 E:1527 ||| NN
processes ||| S:1527 E:1536 ||| NNS
.  ||| S:1536 E:1538 ||| .
